Jump to content


E-Newsletter Signup Like us on Facebook Sign Up For Our e-Newsletter
Photo

Parkinson's Vaccine - Top Experts Unite in European Consortium


  • Please log in to reply
No replies to this topic

#1 Kathrynne Holden, MS

Kathrynne Holden, MS

    Moderator

  • Ask the Dietician Moderators
  • PipPipPip
  • 3,119 posts
  • Locationfacebook.com/Parkinsons.Chew.On.This.

Posted 07 May 2014 - 05:50 PM

Parkinson's Vaccine - Top Experts Unite in European Consortium EU support boosts development of therapeutic vaccines against Parkinson's and Multiple System Atrophy. AFFiRiS leads consortium.
PR-Logo-Newswire.png

 

 

VIENNA, April 28, 2014 /PRNewswire via COMTEX/ -- VIENNA, April 28, 2014 /PRNewswire/ --

An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance the development of two therapeutic vaccine candidates in parallel. They are both unique in the potential for disease modification, something which is sorely missing in PD as well as in MSA. Both candidates target a protein called alpha-synuclein, which plays a key role in the onset and progression of PD and MSA. Additionally, the group attempts to identify biomarkers with diagnostic and prognostic value. Altogether, the consortium exerts medical and scientific key opinion leaders from Germany, France and Austria. The project SYMPATH has been awarded € 6 Mio. from the 7 th   Framework Program of the EU and will run for 48 months.

A consortium of top European scientists has been awarded € 6 Mio. for advancing the clinical development of two therapeutic vaccines for the treatment of both Parkinson's Disease (PD) and Multiple System Atrophy (MSA). The vaccine candidates (PD01A and PD03A) form part of the development pipeline of the Austrian biotech company AFFIRIS AG that leads the consortium and the clinical development in the field. Based on the company's renowned AFFITOME®-technology, both vaccines target the protein alpha-synuclein (alpha-syn) which plays a key role in the onset and progression of PD and MSA, the latter being an orphan disease with no registered therapy. Both candidates have already demonstrated their disease-modifying potential in various preclinical model systems.

 

Read more:

http://www.marketwat...tium-2014-04-28


Best regards,

Kathrynne Holden, MS

--

For a Parkinson Tip of the Day visit:

<!-- m -->http://www.nutritionucanlivewith.com/<!-- m -->




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users